A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03384654 |
|
Recruitment Status :
Completed
First Posted : December 27, 2017
Last Update Posted : December 22, 2022
|
Sponsor:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Janssen Research & Development, LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Drug: Daratumumab Drug: Vincristine Drug: Prednisone Drug: Doxorubicin Biological: Peg-asparaginase Drug: Cyclophosphamide Drug: Cytarabine Drug: 6-mercaptopurine Drug: Methotrexate | Phase 2 |
Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by hematopoietic stem cell transplant (HSCT). Participants with T cell ALL/LL will receive treatment for up to 2 cycles. If disease progression is confirmed, then the participant will discontinue study treatment, complete the End of Treatment Visit, and enter the Posttreatment Period. For those participants who discontinue study drug prior to disease progression, disease evaluations will continue to be performed every 8 weeks until subsequent anticancer therapy is initiated.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 47 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| Actual Study Start Date : | May 14, 2018 |
| Actual Primary Completion Date : | September 22, 2022 |
| Actual Study Completion Date : | September 27, 2022 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Daratumumab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL
Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
|
Drug: Daratumumab
Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2. Drug: Vincristine Participant will receive vincristine 1.5 milligram per meter square (mg/m^2) in cohort 1 and cohort 2. Drug: Prednisone Participant will receive prednisone 40 mg/m^2 in cohort 1 and cohort 2. |
|
Experimental: Cohort 2: T-Cell ALL/LL
Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
|
Drug: Daratumumab
Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2. Drug: Vincristine Participant will receive vincristine 1.5 milligram per meter square (mg/m^2) in cohort 1 and cohort 2. Drug: Prednisone Participant will receive prednisone 40 mg/m^2 in cohort 1 and cohort 2. Drug: Doxorubicin Participant will receive doxorubicin 60 mg/m^2 in cohort 2. Biological: Peg-asparaginase Participant will receive peg-asparaginase 2500 units per meter square (U/m^2) in cohort 2. Drug: Cyclophosphamide Participant will receive cyclophosphamide 1 gram per meter square (g/m^2) once in cohort 2. Drug: Cytarabine Participant will receive cytarabine 75 mg/m^2 in cohort 2. Drug: 6-mercaptopurine Participant will receive 6-mercaptopurine 60 mg/m^2 orally daily in cohort 2. Drug: Methotrexate Participant will receive methotrexate 5 g/m^2 intravenously (IV) in cohort 2. |
Primary Outcome Measures :
- Percentage of Participants with Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) [ Time Frame: Within 2 cycles (each cycle of 28-days) ]Complete response based on the modified National Comprehensive Cancer Network (NCCN) criteria is defined as: Less than 5 percent (%) blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Full recovery of peripheral blood counts: Platelets greater than (>)100*10^9/liter (L) and absolute neutrophil count (ANC) >1.0*10^9/L.
- Percentage of Participants with Complete Response (CR) for T-cell ALL [ Time Frame: End of Cycle 1 (each cycle of 28 days) ]Complete response based on the modified NCCN criteria is defined as: Less than 5% blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Full recovery of peripheral blood counts: Platelets >100*10^9/L and ANC >1.0*10^9/L.
Secondary Outcome Measures :
- Overall Response Rate (ORR) [ Time Frame: approximately 3 years ]ORR is defined as percentage of participants who achieve CR or complete response with only partial hematological recovery (CRi) according to NCCN criteria. NCCN criteria for CR: Less than 5 % blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Full recovery of peripheral blood counts: Platelets (>)100 x10^9/L and ANC >1.0x10^9/L; CRi: Less than 5% blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Partial recovery of peripheral blood counts not meeting criteria for CR.
- Event-Free Survival (EFS) [ Time Frame: approximately 3 years ]EFS is defined as the time from the date of first treatment to the first documented treatment failure (that is [ie], disease progression) or date of relapse from CR or death due to any cause, whichever occurs first. Progressive disease: increase of at least 25% in the absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease.
- Relapse-Free Survival (RFS) [ Time Frame: approximately 3 years ]RFS is defined as the time from CR to relapse from CR or death due to any cause, whichever occurs first. Relapse from CR is defined as: Reappearance of leukemia blasts in the peripheral blood or more than (>) 5% blasts in the bone marrow; Reappearance of extramedullary disease or new extramedullary disease.
- Overall Survival (OS) [ Time Frame: approximately 3 years ]OS is defined as the time from the date of first treatment to the date of death due to any cause.
- Percentage of Participants who are Minimal Residual Disease (MRD) Negative [ Time Frame: approximately 3 years ]Percentage of participants who are MRD negative will be assessed. MRD negative is defined as less than (<) 0.01% abnormal population counts to nucleated mononuclear cells when measured by flow.
- Percentage of Participants who Receive an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) [ Time Frame: approximately 3 years ]The percentage of participants who received an allogeneic HSCT after treatment with daratumumab will be assessed.
- Maximum Observed Plasma Concentration (Cmax) of Daratumumab [ Time Frame: Cohort 1 Cycles 1-9 (each cycle is 28 days); Cohort 2 Cycles 1-2 (each cycle is 28 days) ]The Cmax is the maximum observed plasma concentration.
- Minimum Observed Plasma Concentration (Cmin) of Daratumumab [ Time Frame: Cohort 1 Cycles 1-9 (each cycle is 28 days); Cohort 2 Cycles 1-2 (each cycle is 28 days) ]The Cmin is the minimum observed plasma concentration.
- Number of Participants with Anti-Daratumumab Antibodies [ Time Frame: approximately 3 years ]The incidence of anti-daratumumab antibodies will be assessed as number of participant with anti-daratumumab antibodies.
- Concentration of Daratumumab in Cerebrospinal Fluid (CSF) [ Time Frame: Cohort 1 Cycles 1-9 (each cycle is 28 days); Cohort 2 Cycles 1-2 (each cycle is 28 days) ]Concentration of daratumumab in CSF will be assessed.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 1 Year to 30 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Documented acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) as defined by the criteria below:
- B-cell cohort: Stage 1; ALL in second or greater relapse or refractory to 2 prior induction regimens with greater than or equal to (>=) 5 percent (%) blasts in the bone marrow and aged 1 to less than (<) 18 years. Stage 2; ALL in second or greater relapse or refractory to 2 prior induction regimens with (>=) 5% blasts in the bone marrow and aged 1 to 30 years. LL in second or greater relapse or refractory to 2 prior induction regimens and biopsy proven and with evidence of measurable disease by radiologic criteria and aged 1 to 30 years.
- T-cell cohort: Stage 1; ALL in first relapse or refractory to 1 prior induction/consolidation regimen with (>=) 5% blasts in the bone marrow and aged 1 to <18 years. Stage 2; ALL in first relapse or refractory to 1 prior induction/consolidation regimen with (>=) 5% blasts in the bone marrow and aged 1 to 30 years. LL in first relapse or refractory to 1 prior induction/consolidation regimen biopsy proven and with evidence of measurable disease by radiologic criteria and aged 1 to 30 years
- Performance status greater than or equal to (>=) 70 by Lansky scale (for participants less than [<] 16 years of age) or Karnofsky scale (for participants [>=] 16 years of age)
-
Adequate hematology laboratory values at Cycle 1 Day 1 pre-dosing defined as follows:
- Hemoglobin (>=) 7.5 gram per deciliter (g/dL) ([>=] 5 millimole per liter [mmol/L]; prior red blood cell [RBC] transfusion is permitted)
- Platelet count (>=) 10*10^9 per liter (L) (prior platelet transfusion is permitted)
- Adequate renal function defined as normal serum creatinine for the participant's age or creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) prior to enrollment
-
Adequate liver function prior to enrollment defined as:
- Alanine aminotransferase level less than or equal to (<=) 2.5* the upper limit of normal (ULN),
- Aspartate aminotransferase level (<=) 2.5* ULN, and
- Total bilirubin (<=) 2* ULN or direct bilirubin level (<=) 2.0* ULN
Exclusion Criteria:
- Received an allogeneic hematopoietic transplant within 3 months of screening
- Active acute graft-versus-host disease of any grade or chronic graft-versus-host disease of Grade 2 or higher
- Received immunosuppression post hematopoietic transplant within 1 month of study entry
- Philadelphia chromosome positive (Ph+) B-cell ALL eligible for tyrosine kinase inhibitor therapy
-
Has either of the following:
- Evidence of dyspnea at rest or oxygen saturation (<=) 94 percent (%).
- Known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification
- Received an investigational drug, was vaccinated with live attenuated vaccines, or used an invasive investigational medical device within 4 weeks before the planned first dose of study drug, or is currently being treated in an investigational study
- Known to be seropositive for human immunodeficiency virus (HIV)
-
Any one of the following:
- Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Participants with resolved infection (ie, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded
- Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03384654
Locations
Show 53 study locations
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
| Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Janssen Research & Development, LLC |
| ClinicalTrials.gov Identifier: | NCT03384654 |
| Other Study ID Numbers: |
CR108432 2017-003377-34 ( EudraCT Number ) 54767414ALL2005 ( Other Identifier: Janssen Research & Development, LLC ) |
| First Posted: | December 27, 2017 Key Record Dates |
| Last Update Posted: | December 22, 2022 |
| Last Verified: | December 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Lymphoma Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Cytarabine Prednisone Cyclophosphamide Doxorubicin |
Methotrexate Vincristine Asparaginase Mercaptopurine Daratumumab Pegaspargase Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists |